Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

8.540 +0.610 (+7.69%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
DiaMedica Therapeutics to Participate at Upcoming Investor Conferences
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
4 Penny Stocks Insiders Are Buying ↗
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider... 
Via Benzinga
News headline image
4 Penny Stocks Insiders Are Buying ↗
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider... 
Via Benzinga
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2021 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
News headline image
DiaMedica Therapeutics to Report Second Quarter 2021 Financial Results and Provide a Business Update August 12, 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
From DiaMedica Therapeutics
Via Business Wire
News headline image
DiaMedica Therapeutics Elects Two Industry Veterans to Its Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 15) IVERIC bio, Inc. (NASDAQ:... 
Via Benzinga
Topics Stocks
News headline image
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
News headline image
58 Biggest Movers From Yesterday ↗
Gainers BSQUARE Corporation (NASDAQ: BSQR) shares jumped 206.9% to close at $8.04 on Tuesday on abnormally-high volume possibly amid increased attention from retail investors.... 
Via Benzinga
News headline image
Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge ↗
Toward the end of trading Tuesday, the Dow traded up 0.04% to 34,295.41 while the NASDAQ rose 0.13% to 14,518.98. The S&P traded flat at 4,290.65. The U.S. has the highest... 
Via Benzinga
Topics Stocks
News headline image
Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher ↗
Midway through trading Tuesday, the Dow traded up 0.37% to 34,411.60 while the NASDAQ fell 0.03% to 14,495.75. The S&P also rose, gaining 0.16% to 4,297.63. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
35 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) shares jumped 111.5% to $26.58 after the company announced positive results from its Phase 1b clinical trial of CVL-231... 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results ↗
Following the market opening Tuesday, the Dow traded up 0.40% to 34,420.32 while the NASDAQ fell 0.10% to 14,486.23. The S&P also rose, gaining 0.14% to 4,296.59. The U.S. has... 
Via Benzinga
Topics Stocks
News headline image
DiaMedica Therapeutics Stock Slips On Mixed DM199 Data In Chronic Kidney Disease Patients ↗
DiaMedica Therapeutics Inc (NASDAQ: DMAC) has announced positive interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease (CKD). The... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Stock Gains On Green Signal To Start Pivotal DM199 Trial In Ischemic Stroke ↗
The FDA has signed off DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Investigational New Drug (IND) application to proceed with a pivotal Phase 2/3 study of... 
Via Benzinga
News headline image
DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides a Business Update and Announces First Quarter 2021 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2021 Financials and Provide a Business Update May 6, 2021
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
DiaMedica Therapeutics to Participate in the B. Riley Securities’ Neuroscience Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
51 Biggest Movers From Friday ↗
Gainers Celcuity Inc. (NASDAQ: CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreement with Pfizer to develop and... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.